DDInter1417 DDInter1376
Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the 5-hydroxytryptamine receptor 1A with antagonistic effects. This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Penbutolol {u} (Compound) resembles {v} (Compound) Timolol
Penbutolol {u} (Compound) resembles {v} (Compound) Bupranolol
Penbutolol {u} (Compound) treats {v} (Disease) hypertension
Penbutolol {u} (Compound) binds {v} (Gene) ORM1
Penbutolol {u} (Compound) causes {v} (Side Effect) Insomnia
Penbutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Penbutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Penbutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium citrate
Penbutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Penbutolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Penbutolol (Compound) resembles Timolol (Compound)
Penbutolol (Compound) resembles Bupranolol (Compound)
Penbutolol (Compound) treats hypertension (Disease)
Penbutolol (Compound) binds ORM1 (Gene)
Penbutolol (Compound) causes Insomnia (Side Effect)
Penbutolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Penbutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Penbutolol may lead to a major life threatening interaction when taken with Dolasetron